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Abstract
Respiratory syncytial virus (RSV) is a high priority target for vaccine development. One concern in RSV vaccine
development is that a non-live virus vaccine would predispose for enhanced disease similar to that seen with the
formalin inactivated RSV (FI-RSV) vaccine. Since a mAb specific to RSV G protein can reduce pulmonary
inflammation and eosinophilia seen after RSV infection of FI-RSV vaccinated mice, we hypothesized that RSV G
peptides that induce antibodies with similar reactivity may limit enhanced disease after subunit or other non-live RSV
vaccines. In support of this hypothesis, we show that FI-RSV vaccinated mice administered RSV G peptide vaccines
had a significant reduction in enhanced disease after RSV challenge. These data support the importance of RSV G
during infection to RSV disease pathogenesis and suggest that use of appropriately designed G peptide vaccines to
reduce the risk of enhanced disease with non-live RSV vaccines merits further study.
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Introduction
As the single most important cause of lower respiratory tract
infections in the infant and young child, respiratory syncytial
virus (RSV) is a high priority target for vaccine
development[1,2]. Unfortunately, efforts to develop a safe and
effective RSV vaccine have been unsuccessful to date. The
first candidate vaccine, formalin-inactivated RSV (FI-RSV), was
associated with enhanced disease and also caused two deaths
upon subsequent natural RSV infection [3-6]. This occurred in
children under two years of age but not older children [3-6],
possibly because prior infection patterned for a safe response
to later infection. A study in mice found that prior live virus
vaccination prevented enhanced disease with the formalin
inactivated vaccine [7]. Concern that any other non-live RSV
vaccine may also predispose for vaccine enhanced disease
upon subsequent natural infection has directed development of
RSV vaccines for the RSV naive child away from subunit and
inactivated virus vaccines and to live virus vaccines [8]. Subunit
and inactivated vaccines have been developed and studied in
adults and older children and were not associated with
development of enhanced disease, but unfortunately, none has
yet been shown to be effective [9-11]. Similarly, multiple
attenuated viruses have been developed and evaluated but
none has yet been shown to be both safe and efficacious in
humans [12-14]. The lack of success in developing RSV
vaccines to date and the fact that natural infection provides
limited protection from re-infection and disease indicate that the
task of developing a safe and efficacious live virus vaccine will
be difficult.
Recent studies of the role of antibodies blocking the activities
of the RSV G CX3C chemokine motif suggest a new approach
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to improving the safety of an RSV vaccine. The RSV G has
been shown to modify the immune response to RSV infection
in mice, in particular by contributing to vaccine enhanced
disease, by inducing pulmonary eosinophils, and increasing
production of Th2 cytokines [15-19]. Studies have shown that
the RSV G CX3C chemokine motif is an important contributor
to RSV G -associated immune modulation and disease
pathogenesis [20-23]. Interestingly, an anti-RSV G mAb, mAb
131-2G that blocks RSV G binding to CX3CR1, down-regulated
FI-RSV vaccine enhanced inflammation in vaccinated mice
when given before RSV challenge [24]. This observation led us
to hypothesize that using a vaccine to induce an antibody
response that mimics this RSV G mAb might also decrease FI-
RSV associated enhanced disease and, more importantly,
possibly decrease the risk of enhanced disease after other
non-live virus vaccines. In this study, we demonstrate that
vaccination with an appropriate RSV G peptide that includes
the binding site for mAb 131-2G, and the RSV G CX3C motif,
decreases FI-RSV enhanced disease in mice when
administered at the same time as FI-RSV vaccination. These
data support a role for the RSV G in the challenge virus in the
pathogenesis of enhanced disease after FI-RSV immunization
and suggest that an appropriately constructed RSV G peptide




The study was performed in accordance with the Guide for
the Care and Use of Laboratory Animals of the National
Institutes of Health. The protocol was approved by the Centers
for Disease Control and Prevention (CDC) Institutional Animal
Care and Use Committee (Protocol Number: 1771HAYMOUC).
No surgeries were performed. All efforts were made to
minimize animal suffering during all procedures performed.
Viruses and vaccines
RSV A2 or B1 was propagated in Vero cells (ATCC CCL
881) as previously described [25]. At ~ 80% CPE, the culture
medium was removed from the infected cell monolayers,
serum-free Dulbecco’s Modified Essential Media (SF-DMEM)
(Invitrogen) was added to remove any residual fetal bovine
serum and the virus lysate harvested after two freeze-thaw
cycles. Formalin-inactivated RSV (FI-RSV) was prepared by
incubating 1 part formalin (Sigma Aldrich) with 4,000 parts
clarified RSV at 37°C for 3 days, centrifuging the treated virus
for 1 h at 50,000 x g, 4°C and resuspending the pellet at 1/25
of the original volume in SF-DMEM. The virus was centrifuged
and the supernatant precipitated with aluminum hydroxide
(4mg/ml) overnight at 4°C. The precipitate was pelleted at 1500
x g, 4°C for 15 minutes and resuspended in a 1:100 dilution of
the original volume in SF-DMEM. FI-Vero was prepared as
described above using uninfected Vero cell lysate.
Peptides
The following G protein peptides were synthesized and used
for immunization: two G protein peptides from the Group A
conserved region (amino acids (aa) 163-190) based on an RSV
A2 strain aa sequence (GENBANK, accession number P0342)
(Table 1) and an RSV CH17 A strain (accession number
AAC36325) (Figure S1) aa sequence that includes one amino
acid difference, A to D at position 184, from the RSV A2
sequence and one peptide from the Group B conserved region
(aa 155-206) based on the RSV B18537 strain aa sequence
(accession number P20896) (Figure S1). Sequences from the
group A and B conserved sequences encompass aa 164-176
which is conserved among all strains and the CX3C motif at aa
182-186. An I-Ed-restricted 12-mer peptide from the L protein
(aa 393-405) (accession number AAA84898) of RSV was used
as a negative control immunogen (Table 1). The peptides were
synthesized as previously described [20]. For vaccination
studies, all the peptides were conjugated to keyhole limpet
hemocyanin (CDC Biotechnology Core Facility, Atlanta).
Vaccination, Challenge and Tissue Collection
BALB/c mice (4-6 wks old., The Jackson Laboratory) were
housed in accordance with the guidelines of the CDC
Institutional Animal Care and Use Committee. Mice were i.m.
vaccinated with 106 PFU equivalents of FI-A2 or FI-vero lysate.
Groups of mice were then vaccinated with 50-75 µg of KLH-
conjugated G peptides based on RSV A2 conserved regions,
while a polymerase peptide was used as a negative control.
Initial immunizations consisted of peptide emulsified 1:1 with
TiterMax Gold (TiterMax) administered s.c while booster
immunizations consisted of 50 µg peptide in sterile PBS
administered i.p. at 14 and 28 days post-vaccination. Two
weeks following final G peptide boost, the FI-RSV immunized
mice, with or without the G peptide vaccination, were
anesthetized by i.p. administration of Avertin (2% 2,2,2-
tribromoethanol, 2% tert-amyl-alcohol, 180-250 mg/kg), and
intranasally (i.n.) challenged with 106 PFU of RSV virus, 106
PFU RSV A2, equivalent PFUs of UV-inactivated RSV A2, or
uninfected, vero-lysate control in SF-DMEM. UV-inactivated
RSV A2 was confirmed inactivated by standard plaque assay.
After challenge, at the timepoints indicated, mice were
anesthetized with Avertin and exsanguinated by severing the
right brachial artery. Bronchoalveolar leukocyte (BAL) cells
were harvested by lavaging the lungs with sterile Dulbecco’s
PBS (D-PBS) and BAL cell numbers were counted. Lungs were
Table 1. The RSV G-A2 peptide sequence and location of
the CX3C motif in the G protein.
Peptide  Partial G aa sequence 
a
     
  155 163     190 206
G-A2   FHFEVFNFVPCSICSNNPTCWAICKRIP  
a G-A2 peptide amino acid sequence is from the RSV group A strain A2. The
location of the CX3C motif in the G peptides is underlined. The amino acid
sequence (393-405) for the L control peptide is IINGRWIILLSKFLK.
doi: 10.1371/journal.pone.0083075.t001
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removed and stored at -80°C until use. No fewer than three
mice per treatment per time point were examined.
Histopathology
Formalin-fixed lung tissues and BAL cell morphology were
determined by hematoxylin and eosin staining and light
microscopy analysis as previously described [25]. BAL cells
were fixed to cytoslides with 10% formaldehyde and stained
with hematoxylin and eosin (H&E) as previously described. The
percentages of lymphocytes, polymorphonuclear cells,
macrophages and eosinophils were determined by examining
morphological and staining features of 600 BAL cells per
sample.
Flow Cytometry
The procedure used for extracellular staining of BAL cells
was modified for microculture staining as described [26].
Briefly, BAL cells were blocked in 10% normal mouse serum in
staining buffer (D-PBS with 1% bovine serum albumin) and
then stained with the appropriate combinations of fluoroscein
isothiocyanate-, allophycocyanin-, or phycoerythrin-labeled
anti-CD3ε (T cell marker), anti-CD45R/B220 (B cell marker),
anti-CD11b, anti-polymorphonuclear cell marker (RB6-8C5),
anti-NK cell marker (DX5), and mouse isotype antibody
controls (eBioscience). The distribution of cell surface markers
was analyzed on a BD LSRII flow cytometer using FACSDiva
software (Becton Dickinson, Mountain View, CA) from 10,000
lymphocyte-gated events.
Real-Time qRT-PCR
Total RNA was extracted from homogenized lung tissue
using a RNA purification kit (QIAGEN, Valencia, CA) per
manufacturer’s protocol and expression of the RSV M gene
was determined by real-time qRT-PCR (Stratagene). Results
are presented as relative genome level in PFU equivalents/ml
and were measured against a RSV RNA standard curve.
Cytokine analysis
Cell-free BAL supernatants were assayed for IFN-γ and IL-4
by multiplex bead based assay according to the manufacturer’s
instructions (Bio-Rad) or by ELISA (eBioscience).
Concentration of the cytokine was determined from a standard
curve and data are presented as the mean pg/ml for individual
mice for each group in duplicate.
ELISAs
Mouse sera were screened for whole RSV and anti-peptide
antibody titers using a modified indirect ELISA as previously
described [27]. Briefly, microtiter plates were coated with
immunizing antigen overnight at 4°C. Serial dilutions of sera in
PBS containing 5% milk and 0.1% Tween-20 were added to
the well and incubated for 1 hr at 37°C. The plates were then
washed with washing buffer (PBS containing 0.05% Tween-20)
and incubated for 1 hr at 37°C with horseradish peroxidase-
conjugated goat anti-mouse IgG (H+L, Millipore, Temecula,
CA). After being washed, the plates were developed with ABTS
(KPL) as indicated by the manufacturer, and the optical density
(OD) was measured at 405 nm with a 490 reference filter.
Whole RSV- specific antibody was detected using RSV-
infected (positive antigen) or uninfected (negative antigen)
Vero cell monolayers fixed onto the microtiter plates and
developed using the procedure described above.
RSV microneutralization assay
Heat-inactivated serum from immunized mice was used to
determine neutralizing antibody titers as previously described
[28]. Briefly, two-fold serial dilutions of pooled sera from 8 to 10
mice per pre-challenge vaccination group were mixed with
equal volume RSV strain A2 (final concentration of 1X105 PFU/
well) and incubated for 1 hr at 37°C. After incubation, the virus-
serum mixtures were added to microtiter plates containing 80%
confluent monolayers of Vero cells, and incubated at 37°C for 2
hrs. After virus adsorption, the cell monolayers were overlaid
with DMEM + 10% fetal bovine serum (DMEM+10%FBS),
incubated at 37°C for three days, the monolayers fixed with a
80% to 20% acetone-PBS mixture, and immunostained with a
pool of anti-F and anti-G protein mAbs (clones 131-2A,
131-2G, 130-6D) followed by horseradish peroxidase-
conjugated goat anti-mouse IgG/IgM/IgA (H+L, KPL). Color
was developed with ABTS (KPL) and OD measured at 410 nm.
Each serum pool was assayed in triplicate, and the percent
neutralization at each dilution was determined as the average
value of ((ODvirus infection without antibody – ODvirus+serum antibody)/ODvirus
infection without antibody)*100% for the three replicates.
Statistical Analysis
Data were analyzed for statistical significance using a
Student’s t test, where a P value of <0.05 was considered
statistically significant. Data are expressed as the mean +
standard error of the mean (SEM).
Results
FI-RSV Enhanced Disease Model
In our FI-RSV model, peak inflammation occurs on day 5
post-challenge (p.c.) with live RSV [25] and we chose to
present data on pulmonary inflammation for day 5. As
illustrated in Figure 1, in this model of FI-RSV vaccination in
mice and our method for preparing challenge virus the majority
of the inflammation is not associated just with presence of viral
antigens but requires live virus and, presumably, virus
replication. In FI-RSV vaccinated mice, there was significantly
fewer BAL cells (Figure 1A) and eosinophils (Figure 1B) after
challenge with UV-inactivated RSV A2 or uninfected vero cell
lysate than after live RSV challenge at day 5 p.i. Though
infectious virus was not detected in RSV challenged, FI-RSV
vaccinated mice (data not shown), low levels of RSV RNA were
detected by real time PCR (Figure 1C). In this FI-RSV model,
the marked increase in total number of cells and eosinophils in
the BAL require challenge with live RSV challenge.
Serum antibody response generated by vaccination
The RSV G peptide, aa 163-190 of RSV A2 strain (G-A2),
used in this study contained the G CX3C motif and is relatively
FI-RSV Disease Reduction with RSV G Peptides
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Figure 1.  Vaccine enhanced disease in FI-A2 vaccinated mice after RSV Challenge.  Mice were i.m. vaccinated with formalin
inactivated RSV A2, rested for at four weeks and i.n challenged with either live RSV A2 (FI-A2+A2), UV-inactivated RSV A2 (FI-
A2+UV-A2) or unifected vero cell lysate (FI-A2+vero). Unimmunized mice challenged with live RSV A2 (A2) provide a comparison to
results after acute infection. Unvaccinated RSV challenged mice are compared to FI-RSV vaccinated mice challenged with live RSV
mice and to FI-RSV vaccinated mice challenged with UV-inactivated RSV A2. Data from a separate experiment compares the
inflammatory responses to FI-RSV vaccinated and vero cell lysate challenged mice. On day 5 post-infection, total BAL cell counts
(A), total eosinophil counts (B) and viral RSV M gene mRNA (C) in the lungs of mice were determined. Total eosinophil counts were
calculated by multiplying the total BAL cell counts by the percent eosinophils and presented as total eosinophils in BAL. Significance
was calculated using a Student's t test, comparing mice in each group to mice vaccinated with FI-A2 alone and then challenged with
RSV . * p<0.05 A2 compared to FI-A2+UV-A2 or FI-A2+vero; ** p<0.05 significance FI-A2 + A2 compared to either A2 or FI-A2+UV-
A2 or FI-A2+vero. ND= not detected.
doi: 10.1371/journal.pone.0083075.g001
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conserved among the RSV Group A strains (Table 1). This G
peptide was assessed for its ability to induce antibodies in the
context of formalin-inactivated (FI)-RSV vaccination. BALB/c
mice were i.m. vaccinated with either FI-A2 or FI-Vero control
alone or subsequently immunized with G-A2 or control (L393)
peptide antigens plus adjuvant. The mice receiving peptides
were boosted twice with the respective peptides (Figure 2).
Two weeks after the final boost, the anti-RSV A2 and G
peptide-specific IgG titers were evaluated by an indirect ELISA
assay (Figure 3). Mice immunized with FI-Vero control and a
G-A2 peptide (FI-Vero+G-A2) vaccine developed antibodies
against the whole virus (Figure 3A) and G-A2 peptide (Figure
3B); while mice immunized with FI-Vero alone (FI-Vero) had no
detectable antibodies to either whole virus or G-A2 peptide.
Vaccination with FI-RSV alone (FI-A2) or with G-A2 peptide
(FI-A2+G-A2) induced IgG antibodies against whole virus
(Figure 3A); however, only mice vaccinated with a RSV peptide
developed G peptide specific-antibodies (Figure 3B). Similarly,
FI-A2 vaccinated mice also vaccinated with the control peptide
(FI-A2+L393) developed antibodies against the whole virus
(Figure 3A) and control peptide (data not shown) but not the
RSV G-A2 peptide. All FI-RSV and/or G-A2 peptide vaccinated
mice developed low levels of neutralizing antibodies (Figure
3C).
Vaccination with RSV G peptides reduces FI-RSV
vaccine enhanced disease
We have recently reported that vaccination with RSV G
peptides containing the CX3C motif prevented body weight loss
and pulmonary inflammation in BALB/c mice after acute RSV
infection [29]. To evaluate whether RSV G peptide vaccination
induced an immune response that also decreased FI-RSV
vaccine enhanced disease, FI-RSV and G-A2 or L393 peptide
vaccinated mice were challenged with RSV strain A2 two
weeks after the final vaccination. Lung viral titers, pulmonary
cell infiltration, body weight loss and histopathology were
evaluated at various time points post- challenge.
As expected, mice that received FI-A2 alone developed
substantial pulmonary BAL cell infiltration (Figure 4A) and
eosinophilia (Figure 4B) following A2 challenge, as well as an
increased Th2 type IL-4 cytokine response (Figure 4C), and
increased body weight loss (Figure 5). Increased pulmonary
Th2 type cytokine production and pronounced weight loss are
associated with enhanced FI-RSV vaccine disease in mice
[24,25]. In contrast, mice that received G-A2 peptide, but not
control peptide, in addition to the FI-A2 vaccination, exhibited a
significant decrease in this cellular inflammatory response
(Figure 4A-C) that was seen as early as day 3 post-challenge
(data not shown). Furthermore, the addition of the G-A2
peptide, but not control peptide, to FI-RSV vaccination was
associated with a 32 to 56% decrease in all leukocyte subsets
on day 5 post-challenge, with an even greater decrease (95%,
p=0.002) in DX5+ cells (Table 2). Similar reductions in cell
types were noted at day 3 and day 7 post-challenge in mice
that received both FI-A2 and G-A2 peptide vaccination (data
not shown). G-A2 peptide vaccination had minimal effect on
Th1-type IFN-γ levels (Figure 4D). No infectious virus was
detected by plaque assay of lung homogenates from any of the
vaccinated mice but some viral replication, as measured by
real time PCR, was detected. The viral message levels was
similar for all vaccination schedules with a slight reduction
(p=0.25) in the message levels after G-A2 peptide vaccination
at day 5 post-challenge (Figure 4E). Weight loss was also
significantly decreased (d5 p=0.011, d7 p=0.050) with the
addition of the G-A2 peptide vaccine but not control peptide
vaccine (Figure 5).
Similar to G-A2 peptide vaccination, vaccination with RSV G
peptides spanning the G CX3C motif of RSV strains NY/
CH17/83 (aa 163-190; Group A specific) and B1 (aa 155-206;
Group B specific conserved region) led to a significant
decrease in the number of BAL cells and pulmonary
eosinophils and a marked decrease in IL-4 levels (Figure S1)
(p=0.015 for FI-B1 + G-B1 + B1; p=0.095 for FI-A2+G-CH17+
A2) and weight loss (data not shown) after RSV challenge in
FI-RSV vaccinated mice.
The cellular response to various controls showed that most
of the findings noted above are associated with a response to
live RSV and to a lesser extent cellular or other components in
Figure 2.  Immunization and challenge timeline.  Timeline of vaccination and challenge schedule as described in the Materials
and Methods.
doi: 10.1371/journal.pone.0083075.g002
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Figure 3.  Antibody response against immunizing G peptides in FI-A2 vaccinated mice.  Two weeks following the final boost
and prior to RSV challenge, whole RSV A2 IgG specific titers (A) and G-A2 peptide specific IgG titers (B) in sera from mice
vaccinated with formalin-inactivated RSV A2 alone (FI-A2), FI-A2 and RSV A2 G peptide (FI-A2+G-A2), FI-A2 and control L393
peptide (FI-A2+L393), FI-Vero alone (FI-Vero), or FI-vero and RSV A2 G peptide (FI-Vero+G-A2) were detected by indirect ELISA.
Shown are the absorbance values (OD405) after subtraction of background OD405 values against control antigen. Results are means
of 5 to 10 mice per group and are representative of three independent experiments. (C) Neutralizing antibodies against live RSV A2
in vaccinated animals (1:200 dilution) were detected by a microneutralization assay. Serum from a naïve mouse and anti-RSV F
monoclonal antibody (143-6C) were used as negative and positive controls, respectively. * p<0.05.
doi: 10.1371/journal.pone.0083075.g003
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Figure 4.  Decreased pulmonary cell inflammatory response in FI-A2 and G-A2 peptide vaccinated mice after RSV
challenge.  Mice were i.m. vaccinated with formalin inactivated RSV A2 (FI-A2) and then s.c. vaccinated with RSV A2 G peptide
(FI-A2+G-A2) and control peptide (FI-A2 + L393). Two weeks following the final peptide boost, groups were challenged with live
RSV A2 and the mean numbers of BAL cells/lung (A), total eosinophil counts in the BAL (B), IL-4 levels (pg/ml) (C) and IFN gamma
(D) in the cell-free BAL supernatant, and viral message levels (relative genome equivalent PFU/ml) (E) at day 5 post-challenge
(peak of cell infiltration) were determined. Representative data from five independent experiments are shown. * p<0.05.
doi: 10.1371/journal.pone.0083075.g004
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the challenge preparation (Figure 6). At the peak of cell
infiltration, day 5 post-challenge, the total BAL numbers (Figure
6A) and type of BAL cells (Figure 6B) in the lungs from various
Vero cell control vaccinations and challenges (FI-Vero+Vero,
FI-Vero+G-A2+Vero) were substantially less than in FI-RSV
vaccinated, RSV A2 challenged mice (FI-A2+A2) and similar to
that for FI-A2 vaccinated mice given G-A2 peptide (FI-A2+G-
A2+A2) (Figure 6 A and 6B). These differences between FI-A2
vaccinated, RSV A2 challenged mice and various controls
suggests that elimination of fetal calf serum from the challenge
virus, as expected, decreased the non-RSV component of the
inflammatory response in these studies. Mice immunized with
FI-Vero and the G-A2 peptide, then challenged with RSV A2
(FI-Vero+G-A2+A2) had slightly higher BAL cell numbers
(p=0.161) (Figure 6A) and eosinophil infiltration (p=0.084)
(Figure 6B) than the other control groups, but significantly less
than what was observed in FI-RSV vaccinated, RSV A2
challenged mice. This slight increase in pulmonary
inflammation after the G-A2 peptide alone may have resulted in
part from a lower peptide-specific antibody response without
the FI-RSV vaccination (Figure 3B). Note in Figure 3B that the
anti-G-A2 peptide antibody levels were significantly lower after
FI-Vero plus G-A2 peptide vaccination (FI-Vero+G-A2) than
after FI-RSV plus G-A2 peptide vaccination (FI-A2+G-A2). FI-
Vero immunization and RSV A2 challenge (FI-Vero+A2)
Table 2. Pulmonary leukocytes in FI-RSV and G-A2 peptide
vaccinated mice 5 days after RSV challengea.
Phenotype FI-A2+ A2 (x103) FI-A2+G-A2 +A2 (x103)  
   % Reduction
CD3 146.1 + 20.2 63.7 + 16.3 56
B220 27.1+3.7 14.9 + 3.8 45
DX5 172.8+ 2.4 8.6 + 2.2 95
CD11b 55.9 + 7.7 26.7 + 6.8 52
RB6-8C5 31.1 + 4.3 21.1 + 5.4 32
a Data represent the mean total BAL cells expressing CD3 (T cell marker), CD45R/
B220 (B cell marker), DX5, (NK cell marker), CD11b (macrophage cell marker) or
RB6-8C5 (PMN cell marker) from mice vaccinated with FI-A2 alone or with FI-A2
and G-A2 peptide, five days after RSV A2 challenge. The total number of BAL cells
expressing a particular phenotype was determined by multiplying the mean total
number of BAL cells by the mean percentage of cells expressing that phenotype.
Boldface values indicate a significant decrease (p<0.05) in the number of BAL cells
expressing a particular phenotype with addition of the G-A2 to FI-A2 vaccination.
doi: 10.1371/journal.pone.0083075.t002
Figure 5.  Decreased weight loss in FI-A2 and G-A2 peptide vaccinated mice after RSV challenge.  Mice were i.m. vaccinated
with formalin inactivated RSV A2 (FI-A2) and then s.c. vaccinated with G-A2 or control peptides. Two weeks following the final
peptide boost, FI-A2 and RSV A2 G peptide (FI-A2+G-A2) and control L393 peptide (FI-A2+L393) mice were challenged with 106
PFU live RSV A2 and percent body weight loss were determined. Five independent experiments were performed and combined
(representative) data from two experiments are shown. * p<0.05.
doi: 10.1371/journal.pone.0083075.g005
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induced BAL cell infiltration similar to levels seen in
unimmunized, RSV A2 infected mice (Figure 6C-D).
The degree of lung histopathology associated with FI-RSV
enhanced disease was evaluated. By day 3 post- challenge,
mice vaccinated with FI-A2 alone (Figure 7A) or with the
control peptide (Figure 7B) had heavy perivascular and
peribronchiolar cellular infiltration consisting of large numbers
of lymphocytes, and eosinophils, typical of FI-A2 vaccine
enhanced disease, whereas the addition of G-A2 peptide
vaccination resulted in substantially less (mild) lung infiltration
(Figure 7C). The lung histopathology in FI-Vero vaccinated and
RSV challenged mice was mild to moderate (Figure 7D), while
the lungs of FI-Vero vaccinated and mock-infected mice had
normal histology comparable to that of unimmunized,
uninfected mice (Figure 7E-F). Taken together, these data
suggest that vaccination with a RSV G peptide encompassing
the Group A or Group B conserved region has the ability to
decrease enhanced pulmonary inflammation associated FI-
RSV vaccination.
Discussion
RSV continues to be a high priority for vaccine development.
Unfortunately, the decades of work on developing vaccines
have not identified a clear path to success. The severity of
enhanced disease with natural infection in children given FI-
RSV vaccines in the 1960s has blocked one specific approach
to RSV vaccine development. It raises, and makes it difficult to
allay, concerns about the safety of any non-live virus vaccine
for RSV naïve children. The findings in the present study
suggest that a new approach to non-live RSV virus vaccines is
worth considering. Our results show that appropriately
designed RSV G peptide vaccines can prevent much of the FI-
RSV vaccine enhanced disease in mice. A RSV G peptide
vaccine that substantially decreases FI-RSV enhanced disease
in this animal model is unlikely to present a risk of enhanced
disease in humans and could possibly be used with other
candidate subunit vaccines to make them safer. Another RSV
G peptide vaccine, BBG2Na, has been studied in animals and
adults [30,31]. The peptide, which encompassed aa 130-230 of
RSV G was larger than the ones we studied, and the vaccine
included the albumin-binding domain of streptococcal G as an
adjuvant. The vaccine was effective in animals, showed no
enhanced disease with later RSV infection in humans, but
adverse reactions at the time of vaccination led to
discontinuation of clinical studies. These adverse events were
presumably caused by adjuvant and not the RSV G peptide.
In the present study, the peptides were selected based on
the amino acid sequences of the RSV G; they are relatively
conserved among RSV isolates and include the binding site for
mAb 131-2G and the CX3C motif. There are two relatively
conserved amino acid sequences within the RSV G, one for
group A and one for group B strains that include the CX3C
motif and are large enough to be immunogenic. A vaccine that
includes both of these group A (28 a.a.) and group B (52 a.a.)
conserved region peptides should be capable of inducing
antibodies against all known RSV strains and could protect
from both natural and vaccine associated enhanced disease. A
similarly constructed RSV G peptide vaccine that spans the
central conserved region was recently shown to decrease
pulmonary inflammation seen after primary RSV infection [29].
One major concern about any RSV G based vaccine is
based on studies that have shown that vaccination with intact
or secreted RSV G can cause enhanced inflammation,
including eosinophilia upon RSV challenge [16-18,32]. In this
study, RSV G peptide vaccine, when given at the same time as
FI-RSV vaccination led to significant decreases in four
measures of enhanced disease; i.e. pulmonary cell infiltration,
eosinophilia, IL-4 levels and weight loss. The lack of enhanced
inflammation after peptide vaccination may be due to the
vaccine’s ability to effectively induce antibodies that block RSV
G binding to CX3CR1 and/or because they do not contain
regions of RSV G that induce disease enhancing responses.
To alleviate any concerns about an RSV G peptide vaccine,
however, it will be necessary to understand the mechanisms by
which this vaccine reduced FI-RSV vaccine enhanced disease
in mice, determine if these findings apply to humans and clarify
differences in immunity induced by peptide vaccines, intact G,
and secreted G. We hypothesize that antibodies induced by the
peptide vaccines bind to RSV G and prevent RSV G
associated disease during infection which in turn decreased FI-
RSV enhanced disease. This idea follows from our previous
studies showing that altering the ability of RSV G to bind to
CX3CR1 by using a virus lacking RSV G [25], a virus with a
mutation in the CX3C site [25], or by blocking RSV G binding to
CX3CR1 using anti-G or anti-CX3CR1 mAbs markedly
decreased measures of enhanced disease [24,25,26,33].
These studies suggest that the RSV G, in particular the CX3C
motif, contributes to the enhanced inflammatory response to FI-
RSV vaccination upon RSV challenge. These studies show a
role for RSV G at the time of virus challenge but not a role for
RSV G at the time of FI-RSV vaccination. The hypothesis that
enhanced disease prevented by RSV G peptide immunization
results from induction of antibodies that bind to RSVG during
RSV infection is supported by data showing anti-G peptide
antibodies only in mice vaccinated with both FI-RSV and RSV
G peptide. Another possible explanation for the reduced
inflammation seen after peptide vaccination is a reduction in
virus replication. The RSV message levels detected in the
lungs of FI-RSV vaccinated mice were low and slightly lower
for FI-RSV mice also given the RSV G peptide vaccine but not
significantly so.
The possibility that peptide vaccination might be used to
modify the cellular immune response to RSV challenged after
FI-RSV vaccination has not previously been considered.
Induction of a Th2-type biased adaptive immune response by
FI-RSV is considered a likely contributor to the enhanced
disease with later infection [25,34-38]. Generation of reactive
carbonyl groups during formalin inactivation of the virus may be
responsible for inducing this Th2-biased response [39].
Alternatively, FI-RSV enhanced disease has been associated
with induction of an overabundance of non-neutralizing
antibodies compared to neutralizing antibodies and deposition
of immune complexes [40]. Most attempts to address
enhanced disease have focused on the vaccine and eliminating
induction of the Th2-bias associated with FI-RSV enhanced
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Figure 6.  Pulmonary cell infiltration following FI-RSV and FI-Vero vaccination.  (A) Total BAL cell counts in the lungs of mice
i.m. vaccinated with FI-RSV A2 and live RSV A2 challenged (FI-A2+A2), mice vaccinated with FI-Vero cell lysate supernatant and
then challenged with Vero cell lysate supernatant (FI-Vero+Vero), or mice vaccinated with FI-Vero lysate and G-A2 peptide and
challenged with either RSV A2 (FI-Vero+G-A2+A2) or uninfected, Vero lysate (FI-Vero+G-A2+Vero) (day 5 post-infection). (B) Total
neutrophils (PMN), lymphocytes, (LYM), macrophages (MAC) and eosinophils (EOS) counts in BAL. (C) Total BAL cell counts in the
lungs of mice vaccinated with or without FI-Vero supernatant at day 5 post-RSV A2 challenge. (D) Total PMN, LYM, MAC and EOS
counts in the BAL of mice infected with A2 and mice vaccinated with FI-Vero cell lysate and then challenged with RSV A2 (FI-Vero
+A2) at day 5 post-challenge are shown. Significance was calculated using a Student's t test, comparing mice in each group to mice
vaccinated with FI-A2 alone and challenged with RSV. * p<0.05.
doi: 10.1371/journal.pone.0083075.g006
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Figure 7.  Lung histopathology in vaccinated mice.  Lung histopathology was examined by hematoxylin and eosin staining in (A)
mice i.m. vaccinated with FI-A2 and then challenged with RSV A2 (FI-A2), (B) mice vaccinated with FI-A2 and control L393 peptide
and challenged with RSV A2 (FI-A2+L393), or (C) mice vaccinated with FI-A2 and G-A2 peptide and challenged with RSV A2 (FI-
A2+G-A2) at day 3 post-challenge. The arrows mark areas in inflammatory infiltrates. Control groups were immunized with FI-Vero
cell lysate and challenged with either (D) RSV A2 (FI-Vero) or (E) uninfected, Vero lysate (FI-Vero+Vero). (F) Lung histopathology of
an uninfected, unimmunized BALB/c mouse. The perivascular areas (asterisks) are devoid of inflammatory infiltrates. 40X original
magnification, Scale bar= 200mm.
doi: 10.1371/journal.pone.0083075.g007
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disease and sometimes seen with other subunit RSV vaccines
[41-43]. The present study suggests that the administration of
RSV G peptides that induce antibodies to the central
conserved region of RSV G may decrease enhanced disease,
not by altering immunity induced by the vaccine but by binding
RSV G and altering its role at the time of RSV challenge. We
suspect that a sufficiently immunogenic RSV G peptide vaccine
might decrease inflammatory responses associated with
natural infection following any RSV vaccine.
In conclusion, our data demonstrate that an appropriately
designed RSV G peptide vaccine can prevent enhanced
disease under the most challenging circumstances, i.e. FI-RSV
vaccination, and consequently suggest use of a RSV G peptide
vaccine to improve the safety profile of other RSV vaccines
merits further study. It is possible that co-vaccination with a
RSV G peptide could provide the safe use of a non-live virus
vaccine in the RSV naïve child. These data also support a role
for the RSV G in the challenge virus in FI-RSV enhanced
disease and are another approach to clarifying the
pathogenesis of enhanced disease. RSV G peptide vaccines
and their potential contribution to an RSV vaccine merits further
study.
Supporting Information
Figure S1.  Decreased pulmonary cell inflammatory
response in FI-A2 or FI-B1 and RSV G-CH17 or G-B1
peptide vaccinated mice after RSV challenge. Mice were
i.m. vaccinated with 106 PFU equivalents of formalin inactivated
(FI) RSV A2 (FI-A2) or FI-RSV B1 and then s.c. vaccinated
with RSV CH17 G peptide (FI-A2+G-CH17) or RSV B1 G
peptide (FI-B1+G-B1) as described in the Materials and
Methods. Two weeks following the final boost with respective
peptides, groups were challenged with either live RSV A2 (FI-
A2+G-CH17) or RSV B1 (FI-B1+G-B1) and mean numbers of
BAL cells/lung (A-B), total eosinophil counts in the BAL (C-D),
and IL-4 levels (pg/ml) in the cell-free BAL supernatant (E-F)
were determined. Error bars represent the SEM. Significance
was calculated using a Student's t test comparing mice
vaccinated with FI-RSV alone and mice vaccinated with both
FI-RSV and respective RSV G peptide at indicated time points
after RSV challenge. Representative data from three
independent experiments are shown. * p<0.05 G-CH17 peptide
represents the amino acid sequence (aa 163-190) for the RSV
group A strain CH17
(FHFEVFNFVPCSICSNNPTCWDICKRIP), and G-B1 peptide
(PPKKPKDDYHFEVFNFVPCSICGNNQLCKSICKTIPSNKPKK
KPTIKPTNKP) represents the amino acid sequence (aa
155-206) for the RSV group B strain B18537.
(TIF)
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